Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: sam who wrote (5096)	8/6/1998 5:40:00 PM
From: Intel Trader	Read Replies (1) \| Respond to of 6136

FWIW, I'd agree with Peter re current mkt conditions influencing Agouron's share price. I called Claudia B. at Agouron yesterday and she confirmed an ICAAC conference about 23 September 1998 that they would be at. She also talked about an NDA for a lung cancer drug (AG3340?) that was upcoming in calendar year 2000. Further, more information about the oncology division formation would be issued about mid to late September, 1998. Lastly, more developments with Remune + Viracept are due in 6-7 months from now. I hope that this information is not too vague and is substantially correct, but it is compiled from some rather poorly written notes. We spoke for a few minutes, and the impression I got was that Agouron's investor relations people do have concern for the smaller shareholders who would include us. She seemed to be more responsive and willing to share more information than other IR sections at companies that I've contacted before. Best regards to all, it

To: sam who wrote (5096)	8/6/1998 5:43:00 PM
From: Joe E.	Read Replies (1) \| Respond to of 6136

Nice price comeback today. When I first read the 10K I thought that AGPH was dedicating all of their cash flow to R+D, but after some study it looks to me now that they should be able to build up their cash and investment position by maybe 30% per year for the next few years. This while increasing R+D significantly. I think a growing cash position will be positively perceived. Alternatively, they may make another drug or company acquisition. My model has a current value of roughly $40. For some reason revenue after fiscal 2000 seems very hard to forecast, though, so there might be other opinions.